Recent advances in partial cellular reprogramming using OSKM factors show promise in extending healthspan and treating age-related diseases, with biotech firms accelerating towards human trials. New r...
Emerging research links aging oral microbiome with senescent cells to amplify systemic inflammation, driving diseases like Alzheimer’s and offering new intervention targets such as probiotics an...
Recent studies show targeted epigenetic reprogramming with Yamanaka factors rejuvenates neurons, reversing cognitive decline in aged mice and reducing Alzheimer’s markers, with AI enhancing safe...
New research identifies IRF7 as a critical driver of unstable atherosclerotic plaques, offering a potential therapeutic target to reduce cardiovascular events through innovative clinical trials and te...
Recent studies show that targeting engrams with partial reprogramming factors improves memory in mouse models, offering a potential therapy for Alzheimer’s and age-related cognitive decline. New...
A 2024 study in Nature Aging shows transferring young gut bacteria to aged mice rejuvenates intestinal stem cells via Wnt signaling, suggesting FMT’s potential for age-related disorders. Recent ...
A Nature Aging study shows mitochondrial stress enhances senolytic drugs like navitoclax, improving senescent cell removal by 40% with metabolic interventions. New research reveals mitochondrial stres...
Recent studies show FMT from young donors improves gut health and cognitive function in aging, with FDA updates and probiotic innovations paving the way for scalable therapies. New research reveals FM...
A Nature Communications study shows engineered small extracellular vesicles with platelet proteins restore heart rhythm in rats, offering a safer alternative to pacemakers and gene therapies. Innovati...
Recent studies show small molecules efficiently mimic Yamanaka factors to reverse epigenetic aging, with clinical trials on the horizon, offering a safer alternative to gene therapies. Advancements in...
